Fairmont Hotel Vancouver Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Purinergic Signaling (J5)


Organizer(s) Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson
January 24—28, 2016
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Discounted Abstract Deadline: Sep 29, 2015
Abstract Deadline: Oct 29, 2015
Scholarship Deadline: Sep 29, 2015
Discounted Registration Deadline: Nov 24, 2015

Sponsored by Bayer HealthCare Pharmaceuticals and Roche


Summary of Meeting:
Purines including ATP and adenosine play dual roles as intracellular mediators of metabolism and as critical extracellular signaling molecules, the latter via 19 purinergic receptors that control responses to stress and injury. This meeting will integrate rapidly emerging information about the regulation of purine release from cells (in vesicles and via channels and transporters); signaling via membrane-associated receptors (adenosine, P2X and P2Y) and extracellular metabolism (via CD73, CD39 and other ecto-enzymes); and new structural information that is facilitating drug discovery. These processes mediate tissue responses to a continual flux of signaling purines in the extracellular space that profoundly influence inflammatory diseases, tissue repair and immune function. A focus on the effects of hypoxia, metabolic stress and cytokines will fill gaps in our current knowledge of how these factors influence signaling during the evolution of acute and chronic inflammation. An understanding of how purinergic signals are dynamically regulated is needed to identify improved therapies, e.g., for cancer immunotherapy, since tumors exploit these pathways to avoid immune surveillance. Of particular interest is the growing realization that purinergic regulation controls remodeling of inflamed tissues and the functions of innate and adaptive immune cells, endothelial cells and platelets. The significance of extracellular purines in multiple tissues will be covered. The meeting should generate new mechanistic and therapeutic concepts. Prior meetings have defined the triad of purinergic "players" (channels, receptors and enzymes) generally in unstressed animals. The meeting will focus on the paradigm-shifting realization of dynamic purinergic regulation in the setting of disease progression.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, January 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, January 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, January 29 in order to fully experience the meeting.

SUNDAY, JANUARY 24

16:00—20:00
Arrival and Registration

British/Columbia Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

British/Columbia Foyer

MONDAY, JANUARY 25

07:30—08:30
Breakfast

Pacific Ballroom
08:30—10:00
Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keynote Address (Joint)
Meeting has ended...abstracts no longer viewable online.

British/Columbia Ballroom
* Barbara Seliger, Martin Luther University, Germany

* Joel Linden, La Jolla Institute for Allergy and Immunology, USA

Simon C. Robson, Beth Israel Deaconess Medical Center, USA
Purinergic Signaling and Conditioning of Inflammatory Responses in Clinical Disease

Robert D. Schreiber, Washington University School of Medicine, USA
Personalizing Cancer Immunotherapy

10:00—10:20
Coffee Break

British/Columbia Foyer
10:20—12:30
Purine Release
Meeting has ended...abstracts no longer viewable online.
Mechanisms of purine release from cells.

British Ballroom
* Gerhard Dahl, University of Miami, USA
ATP Release through Pannexon Channels.

Christa E. Müller, Universität Bonn, Germany
Medicinal Chemistry of Purinergic Signalling

Leon J. DeLalio, University of Virginia, USA
Short Talk: Localization of Panx1 to Caveolae Facilitates ATP Release in the Vasculature

Marta Radwan, University of Bath, UK
Short Talk: The Mouse Pannexin1-P2X7 Receptor Interactome

Francesco Di Virgilio, University of Ferrara, Italy
ATP: A Novel Constituent of the Tumor Microenvironment affecting Tumor Growth and Metastatic Spreading

10:20—12:15
Tumor Microenvironment and Effector Cells
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Jerome Galon, INSERM U872, Cordeliers Research Center, France

Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany
Adoptive T Cell Therapy

Barbara Seliger, Martin Luther University, Germany
Escape of Tumors from Immune Cell Recognition by Modulating MHC Class I Antigen Processing Components

Fathia Mami-Chouaib, Institut Gustave Roussy, France
Paradoxical Role of TGF-beta in Promoting CTL Effector Functions within Epithelial Tumor Microenvironment by Triggering CD103 Integrin Expression and Signaling

David C. Clever, National Institutes of Health, USA
Short Talk: Inhibition of T Cell Oxygen Sensing Promotes Pulmonary Effector Responses and Limits Tumor Metastasis

12:30—13:00
Poster Setup

Pacific Ballroom
13:00—22:00
Poster Viewing

Pacific Ballroom
12:30—14:30
On Own for Lunch

14:30—16:30
Workshop 1: ATP Release and Metabolism

British Ballroom
* Brant Isakson, University of Virginia, USA

* Gennady G. Yegutkin, University of Turku, Finland

Alexander S. Keller, University of Virginia, USA
Expression of Pannexin Isoforms in Mouse Erythrocytes

Miranda E. Good, University of Virginia, USA
Smooth Muscle Cell Pannexin1 can Regulate Myogenic Reactivity in Cerebral Arteries

Kishio Furuya, Nagoya University, Japan
Stretch Induced ATP Release via Hemichannels Accelerates Wound Closure in Keratinocyte by Ca2+ Influx from TRPC6

Juan Pablo Huidobro-Toro, Universidad de Santiago de Chile, Chile
A Potassium Rich Diet Increased Mechanically Evoked ATP Release from Rat Mesenteric Endothelial Cells; Clinical Implications

Christian Renn, University of Bonn, Germany
Comparison of ecto-5‘-nucleotidase (CD73) Assays for the Identification and Characterization of Inhibitors

Florian Wirsdörfer, University Hospital Essen, Germany
Role of CD73 and Extracellular Adenosine in Radiation-Induced Lung Fibrosis

Gilles Kauffenstein, Angers University, France
Vascular Changes in Pseudoxanthoma Elasticum - Potential Link to Extracellular Purine Metabolism

Maria Serena Longhi, Beth Israel Deaconess Medical Center, USA
Aberrant Regulation of CD39 Expression by Th17 Cells in Inflammatory Bowel Disease

14:30—16:30
Workshop

Columbia Ballroom
* Jerome Galon, INSERM U872, Cordeliers Research Center, France

Matthew Coelho, University College London - The Francis Crick Institute, UK
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Daniel Corey, Stanford University, USA
Reverse Engineering B. Schlosseri Developmental-regulated Cell Death Programs for Cancer Immunotherapy

Mirjana Efremova, Medical University of Innsbruck, Austria
Modeling Immunoediting of the Tumor during Progression

Mirjam H.M. Heemskerk, Leiden University Medical Center, Netherlands
TCR Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma

Nikhil S. Joshi, Yale University School of Medicine, USA
Investigating Endogenous Anti-tumor T Cell Responses in Native Tumor Microenvironments

Rachel Yamin, Hebrew University, Israel
Profiling of Ubiquitin Modifications in NK Cell Activation

Iryna Saranchova, University of British Columbia, Canada
Molecular Studies on the Primary to Metastatic Transition

16:30—17:00
Coffee Available

British/Columbia Foyer
17:00—19:00
Purine Metabolism
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* Norbert Sträter, University of Leipzig, Germany
Structure and Function of CD39 and CD73 in Purinergic Signalling

* Elizabeth Hartland, University of Melbourne, Australia
Microbial NTPDases and their role during infection

Ridong Chen, APT Therapeutics, Inc., USA
Human Apyrase as a Paradigm-shifting Therapy for Cardiovascular Diseases with Undetectable Bleeding Risk

Cynthia St. Hilaire, University of Pittsburgh, USA
Short Talk: In Vivo Disease Modeling Using Patient-Derived iPSCs: CD73-Deficiency Promotes Osteogenic Differentiation and Calcification

17:00—19:00
Immune Signature and Biomarkers
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Barbara Seliger, Martin Luther University, Germany

Jerome Galon, INSERM U872, Cordeliers Research Center, France
Importance of the Immune Infiltration and Cancer Classification

Francesco M. Marincola, Sidra Medical and Research Center, Qatar
A Panoramic View of Tumor Rejection Induced by Immune Therapy

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T Cell Recognition and Tumor Resistance in Human Cancer

Daniela Schmid, Dana-Farber Cancer Institute, USA
Short Talk: T Cell-Targeted Nanoparticles for Delivery of Immunomodulatory Molecules

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pacific Ballroom
19:30—22:00
Poster Session 1

Pacific Ballroom

TUESDAY, JANUARY 26

07:30—08:30
Breakfast

Pacific Ballroom
08:00—08:30
Poster Setup

Pacific Ballroom
08:30—17:00
Poster Viewing

Pacific Ballroom
08:30—11:45
Adenosine and P2Y Structure and Medicinal Chemistry
Meeting has ended...abstracts no longer viewable online.
New developments in adenosine receptor signaling.

British Ballroom
* Mark Yeager, University of Virginia School of Medicine, USA
Structural Biology of Adenosine Receptor G-Protein Complexes

Stefano Moro, University of Padova, Italy
Short Talk: Could Adenosine Engage its Receptors with an Alternative 1:1 Stoichiometry? New Insights from Supervised Molecular Dynamics (SuMD) Simulations

Ruben Abagyan, University of California, San Diego, USA
Modeling and Structure Based Discovery of Allosteric Modulators

Edward P. Amento, Molecular Medicine Research Institute, USA
Short Talk: Positive Allosteric Modulation of the Adenosine A2a Receptor Alleviates PMA-Induced Acute Contact Dermatitis in Mice

* Kodi S. Ravichandran, University of Virginia, USA
Don't Let Death Do Us Part: Pannexin Channels in Communication between Apoptotic Cells and Phagocytes

* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA
Structure-Based Design of P2Y Receptor Ligands

08:30—11:30
Systems Biology and Dysregulation in Cancer
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Francesco M. Marincola, Sidra Medical and Research Center, Qatar

James P. Allison, University of Texas MD Anderson Cancer Center, USA
Tumor Targeting using Checkpoint Antibodies

Carlo M. Croce, Ohio State University, USA
Causes and Consequences of microRNA Dysregulation in Cancer

Ofer Mandelboim, Hebrew University, Israel
Importance of Bacteria in Modulating NK Cell Response against Tumors

Francesca Finotello, Innsbruck Medical University, Austria
Short Talk: Quantification of Tumor-Infiltrating Lymphocyte Subpopulations using Imaging and Sequencing Data

Spencer C. Wei, University of Texas MD Anderson Cancer Center, USA
Short Talk: High-Dimensional Cytometry Reveals Novel T cell Populations that Arise in the Absence of CTLA-4

09:50—10:10
Coffee Break

British/Columbia Foyer
11:45—12:30
Lunch

Pacific Ballroom
12:00—14:30
Poster Session 2

Pacific Ballroom
14:30—16:30
Workshop 2: Purinergic Receptors and Cancer

British Ballroom
* Silvia Deaglio, University of Turin, Italy

* Simon C. Robson, Beth Israel Deaconess Medical Center, USA

Sara Serra, University of Turin and Human Genetics Foundation, Italy
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia (CLL) Microenvironment

Bruce Cronstein, New York University, Langone Medical Center, USA
Ticagrelor Inhibits Spread of Multiple Myeloma to Bone

Jessica Lynn Bowser, University of Texas MD Anderson Cancer Center, USA
CD73 Mediates Epithelial Integrity in Endometrial Carcinoma: Is Protecting the Barrier Promoting Tumor Immunosuppression

Amanda S. MacLeod, Duke University, USA
IL-27-Inducible ENTPD1 Suppresses Protective Skin-Resident Immunity upon UV Damage and Inhibits DNA Repair

Odd Lilleng Gammelgaard, University of Southern Denmark, Denmark
Dual Epitope Targeting of CD73 Exhibits Potent Anti-Cancer Activity

Daniela Sauma, Facultad de Ciencias, Universidad de Chile, Chile
CD73-Mediated Adenosine Production Promotes Stem Cell-Like Properties in Mouse Tc17 Cells

Miki Kamiyama, University of Tokyo, Japan
ASK1 Regulates Tumor Lung Metastasis and Platelet Functions through ADP Signaling

16:30—17:00
Coffee Available

British/Columbia Foyer
17:00—19:00
Drugs Targeting Adenosine Receptors
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* Bruce Cronstein, New York University, Langone Medical Center, USA

Tomyuki Kanda, Kyowa Hakko Kirin Co., Ltd., Japan
Adenosine A2A Receptor as Therapeutic Target for Parkinson's and Neurodegeneration

Joel Linden, La Jolla Institute for Allergy and Immunology, USA
Inhibition of Sterile Inflammation by Adenosine

* Pnina Fishman, Can-Fite BioPharma Ltd., Israel
Utilizing the A3 Adenosine Receptor as a Target to Combat Cancer: From Lab to Labeling

Carmen Corciulo†, New York University Medical Center, USA
Short Talk: Adenosine A2A Receptor, But Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats

17:00—19:00
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Therapy
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Curative Immunotherapy Using CAR- and TCR-Based T Cells

Gerold Schuler, University Hospital of Erlangen, Germany
Monocyte-Derived Dendritic Cells as Vaccines: Beyond Simple Induction of T Cells

Ronald Levy, Stanford University, USA
Targeting the Immune System while Targeting the Cancer Customized vs. Off-the-Shelf Therapies

Karl-Johan Malmberg, Radiumhospitalet, Norway
Short Talk: Critical Role of CD2 Co-Stimulation in Adaptive NK Cell Responses Revealed in NKG2C-Deficient Humans

19:00
On Own for Dinner
No registration fees are used to fund alcohol served at this function.


WEDNESDAY, JANUARY 27

07:30—08:30
Breakfast

Pacific Ballroom
08:30—11:45
Cancer Immunotherapy I
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* Joel Linden, La Jolla Institute for Allergy and Immunology, USA

Gennady G. Yegutkin, University of Turku, Finland
Cellular Purine Homeostasis as a Complex and Coordinated Network Controlling Tumor Invasion and Migration

John Stagg, University of Montréal, Canada
CD73-mediated Adenosine Signaling in Human Cancers

* Michail Sitkovsky, Northeastern University, USA
Conceptually Novel “Anti-Hypoxia-A2A-Adenosinergic” Checkpoint Inhibitors to Improve Immunotherapies and Chemotherapies of Cancer

Caglar Cekic, Bilkent University, Turkey
Adenosine Regulation of Myeloid Cells in Solid Tumors

Erik Wennerberg, Weill Cornell Medical College, USA
Short Talk: Adenosine Regulates Radiation Therapy-Induced Anti-Tumor Immunity

Arabella Young, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Co-inhibition of Adenosine Generation and Signaling Improves Anti-Tumour Immune Responses

08:30—11:30
Immune Suppression and the Role of Paracrine Factors in Modulating Immune Suppression
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Rolf Kiessling, Karolinska Institute, Sweden

Sandra Demaria, Weill Cornell Medical College, USA
Harnessing Radiotherapy to Overcome Tumor Resistance to Immunotherapy

Joel Le Maoult, Institut Universitaire d'Hématologie, France
Role of HLA-G in Human Tumors

Sjoerd H. van der Burg, LUMC, Netherlands
HLA-E in Cancer: From Immune Escape to Therapeutic Target?

Erik Thiele Orberg, Johns Hopkins School of Medicine, USA
Short Talk: The Myeloid Immune Signature of Enterotoxigenic Bacteroides fragilis-induced Murine Colon Tumorigenesis

Byron Kwan, Massachusetts Institute of Technology, USA
Short Talk: Integrin-targeted Combination Immunotherapy Improves Survival in a Broad Spectrum of Tumor Types

09:50—10:10
Coffee Break

British/Columbia Foyer
11:45—13:00
Poster Setup

Pacific Ballroom
13:00—22:00
Poster Viewing

Pacific Ballroom
11:45—17:00
On Own for Lunch

16:30—17:00
Coffee Available

British/Columbia Foyer
17:00—19:00
Cancer Immunotherapy II
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* John Stagg, University of Montréal, Canada

Kris F. Sachsenmeier, MedImmune LLC, USA
MEDI9447: Targeting CD73 in the Tumor Microenvironment

Phillip K. Darcy, Peter MacCallum Cancer Centre, Australia
Enhancing Adoptive Cellular Therapy by Targeting Tumor-Induced Immunosuppression

* Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Strategies for Combination Cancer Immunotherapies that Target Adenosine

Dora Hammerl, La Jolla Institute, USA
Short Talk: Intratumeral Injection of Microparticles Containing the A2A Receptor Antagonist SCH58261 Slow Tumor Growth and Metastasis More Effectively than Systemic Drug Administration

17:00—19:00
Novel Immunotherapeutic Approaches and Antibody Therapies
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Michele Maio, University Hospital of Siena, Italy

Gregory Lawrence Beatty, University of Pennsylvania, USA
Activating Innate and Adaptive Immunity by CD40 Agonists

Nils Lonberg, Bristol-Myers Squibb, USA
Immune Checkpoints and Combination Therapy

Susanne Steggerda, Calithera Biosciences, Inc., USA
Short Talk: Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pacific Ballroom
19:30—22:00
Poster Session 3

Pacific Ballroom

THURSDAY, JANUARY 28

07:30—08:30
Breakfast

Pacific Ballroom
08:30—11:45
Purinergic Signaling in the CNS
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* Kazuhide Inoue, Kyushu University, Japan
Purinergic Regulation of Microglia in Neuropathic Pain

* Maria P. Abbracchio, University of Milan, Italy
Purinergic Regulation of Oligodendrocyte Precursor Cells and Myelination

Masahiro Mishina, Nippon Medical School, Japan
Brain Imaging of Adenosine Receptors

Francisco J. Quintana, Harvard Medical School, USA
Control of Autoimmune Inflammation by CD39 (ENTPD1)

Mallikarjunarao Ganesana, University of Virginia, USA
Short Talk: Increase of Transient Adenosine Release Frequency from Ischemic Brain

Catia Lambertucci, University of Camerino, Italy
Short Talk: Partial Agonists of A1 Adenosine Receptors as Neuroprotective Agents

08:30—11:45
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
Thomas Gajewski, University of Chicago, USA
Molecular Mechanisms of the T Cell-Inflamed Tumor Microenvironment: Implications for Immunotherapy

Rolf Kiessling, Karolinska Institute, Sweden
Counteracting Tumor-Induced Immune Suppression by Checkpoint Blockade and Inhibitors of CSF-R1

David H. Munn, Georgia Regents University, USA
IDO, PTEN and Activated Tregs in the Tumor Microenvironment

Robert Leone, Johns Hopkins University School of Medicine, USA
Role of Metabolic Changes on the Immune Response

Robbert M. Spaapen, Sanquin Research, Netherlands
Short Talk: Intramolecular MHC Class I Regulation Affects Functional Antigen Presentation

Anushka Dongre, Whitehead Institute for Biomedical Research, USA
Short Talk: Understanding the Contribution of the Epithelial to Mesenchymal Transition (EMT) to Immuno-suppression in Breast Carcinomas

09:50—10:10
Coffee Break

British/Columbia Foyer
11:45—14:30
On Own for Lunch

14:30—16:30
Workshop 3: P2 Purinergic Receptors as Drug Targets

British Ballroom
* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA

* Christa E. Müller, Universität Bonn, Germany

Aranzazu M. Mediero, New York University School of Medicine, USA
Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo via an Adenosine Dependent Mechanism

Guido Beldi, University of Bern, Switzerland
P2X1 Regulated IL-22 Secretion by Innate Lymphoid Cells is Required for Efficient Liver Regeneration

Stephanie Weinhausen, University of Bonn, Germany
Binding Site of the Allosteric P2X4 Receptor Modulator Ivermectin

Ronald Sluyter, University of Wollongong, Australia
P2X7 Receptor Activation Mediates Amyotrophic Lateral Sclerosis-Associated Mutant Superoxide Dismutase 1 Release from Murine Motor Neurons

Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Germany
Nanobodies That Block Gating of the P2X7 ion Channel Ameliorate Inflammation

Alicia Mathers, University of Pittsburgh, USA
Signaling Through the P2X7 Receptor Induces an Acute Psoriasis-Like Inflammatory Response in the Skin

Mabrouka Salem, Laval University, Canada
P2Y6 Receptor Deletion Exacerbates Intestinal Inflammation Through Th17 Recruitment

Angela Schulz, University Leipzig, Medical Faculty, Germany
P2Y14 Influences Insulin Secretion

16:30—17:00
Coffee Available

British/Columbia Foyer
17:00—18:45
P2 Receptors
Meeting has ended...abstracts no longer viewable online.

British Ballroom
* Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Germany

* Rosaria Volpini, Università degli Studi di Camerino, Italy
P2 Receptor Ligands: Overview and Updates

Marco Cattaneo, Università degli Studi di Milano, Italy
P2Y12 Receptors: Structure and Function

Mufeng Li, NINDS, National Institutes of Health, USA
Structure and Gating Mechanisms of ATP Activated P2X Receptor Channels

17:00—18:45
Targeted Therapies and Combination Therapies
Meeting has ended...abstracts no longer viewable online.

Columbia Ballroom
* Barbara Seliger, Martin Luther University, Germany

Adrian Bot, Kite Pharma, Inc., USA
Optimizing the Translation of Genetically Programmed T Cells to Safe and Potent Therapies

Leisha A. Emens, Johns Hopkins School of Medicine, USA
Enhancing Cancer Vaccine Activity with Tumor-Specific Monoclonal Antibodies

Michele Maio, University Hospital of Siena, Italy
Sequential Therapy of Checkpoint Inhibitors with Targeted Therapies

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions

British Ballroom
* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

Columbia Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Pacific Ballroom
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Pacific Ballroom

FRIDAY, JANUARY 29

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bayer HealthCare Pharmaceuticals Roche

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



MedImmune


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676